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Expression of type I and II interferon (IFN) was evaluated in gut-associated lymphoid tissue (GALT) and peripheral blood
mononuclear cells (PBMCs) of HIV-1-positive patients on long-term, suppressive, antiretroviral therapy before and after
probiotic supplementation. IFNα subtypes and IFNβ were expressed at higher levels in GALT compared to PBMC, whereas an
opposite trend of expression was recorded for IFNγ. An increase of IFNα6, IFNα10, IFNα14, IFNα17, and IFNα21 and a
decrease of IFNγ were observed in both anatomical sites after probiotic supplementation.
1. Introduction
A strong relationship between type I interferon (IFN)
response and disease progression in chronic HIV-1 and sim-
ian immunodeficiency virus (SIV) infection exists [1]. IFNα
was recently identified as the predominant type I IFN
expressed in plasma during untreated, chronic HIV-1 infec-
tion [2]. However, IFNα is not a unique cytokine; it consists
of a group of at least 12 structurally related subtypes with
specific biological activity and which might be differentially
expressed during viral infection [3]. A recent comprehensive
direct study of IFNα subtype expression in HIV-1 infection
and of the type I IFN signature in specific anatomical sites,
such as the gastrointestinal tract, showed a compartmental-
ized IFN-I response during chronic untreated HIV-1 infec-
tion, with IFNβ being more predominant in the gut. [4]. In
this regard, it is not completely clear whether constitutive
type I IFN production in the intestine is driven by commen-
sal microbial signals and/or modulated by dietary, probiotic,
and prebiotic interventions. However, the protective effects
of commensal and probiotic bacteria in the intestine have
been shown to be mediated, in part, by the induction of
type I IFN, and, more importantly, IFNAR1−/− mice have
increased susceptibility to dextran sodium sulfate-induced
acute colitis [5, 6].
Thus, this topic deserves investigation as a gastrointesti-
nal dysfunction associated with altered microbiome compo-
sition and a severe enteropathy is one of the hallmarks of
HIV-1 pathogenesis [7].
Given that type I IFN is thought to have detrimental
effects during HIV-1 infection and that each IFNα subtype
displays different anti-HIV-1 activity [8], the expression of
all IFNα subtypes, IFNβ, and IFNγ was evaluated both in
gut-associated lymphoid tissue (GALT) and peripheral blood
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mononuclear cells (PBMCs) of antiretroviral therapy- (ART-)
treated HIV-1 patients. Moreover, since probiotics have
shown promising effects in improving gut function in
HIV-1 subjects [7], their role in modulating GALT- and
PBMC-associated type I and II IFN expression was ana-
lyzed in ART-treated HIV-1 patients after several months
of a twice daily dietary supplement with a multistrain pro-
biotic formulation [9].
2. Material and Methods
2.1. Patients. Ten Caucasian HIV-1-positive patients on
long-term suppressive ART were recruited at the Division
of Infectious Diseases, Department of Public Health and
Infectious Diseases, Hospital of “Sapienza” University of
Rome (Italy). All HIV-1-infected patients received a high
concentration of lyophilized multistrain probiotic supple-
ment (Lactobacillus plantarum DSM 24730, Streptococcus
thermophilus DSM 24731, Bifidobacterium breve DSM
24732, Lactobacillus paracasei DSM 24733, Lactobacillus
delbrueckii subsp. bulgaricus DSM 24734, Lactobacillus aci-
dophilus DSM 24735, Bifidobacterium longum DSM 24736,
and Bifidobacterium infantis DSM 24737) twice a day for
six months [9, 10]. This formulation is commercialized
as Vivomixx in EU, Visbiome in USA, and the DeSimone
Formulation in Korea [9]. The probiotic preparation was
administered per os at a daily dosage of 1.8× 1012 live bac-
teria. The study was approved by the institutional review
board (Sapienza University of Rome), and all study partic-
ipants gave written informed consent.
2.2. Laboratory Procedures and Analysis Sampling. Patients
were sampled for peripheral blood (20mL) and underwent
endoscopic procedures. Colonic washing was carried out
by PEG administration 24 hours before the examination.
The endoscopic procedure was performed with conscious
sedation (midazolam 5mg/iv) using large cup forceps (Radial
Jaw4,BostonScientific,Natick,MA,USA).AllHIV-1-positive
patients underwent a total colonoscopy and retrograde
ileoscopy for at least 10 cm of distal ileum with conven-
tional or slimcolonoscope (modelCForPCF160AI,Olympus
Medical Europe GmbH, Hamburg, Germany). We obtained
specimens from the terminal ileum, cecum, ascending, trans-
verse, and descending colon. Peripheral blood mononuclear
cells (PBMCs) and lamina propria lymphocytes (LPLs) were
stored as dried pellets for RNA extraction and subsequent
evaluation of IFNα subtypes, IFNβ, and IFNγ levels.
2.3. PBMCandLPLProcessing.Peripheral blood sampleswere
collected in tubes containing ethylene-diamine-tetraacetic
acid (EDTA), and plasma was previously separated by centri-
fugation. Blood was processed to obtain PBMCs by Ficoll gra-
dient centrifugation (Lympholyte, Cedarlane Labs, Hornby,
Ontario, Canada). Gut biopsies from each intestine site were
pooled and processed. Briefly, biopsies collected in RPMI
1640werewashed twicewithEDTAwashmedia, resuspended,
and incubated for 1 hour at room temperature in 5mM
EDTA solution. Supernatant containing intraepithelial lym-
phocytes was removed, and biopsies were digested by 1-hour
incubation at 37°Cwith 1mg/mL collagenase (Sigma-Aldrich,
Milan, Italy) and 1.5U DNAse I (Sigma-Aldrich, Milan,
Italy), allowing the isolation of LPLs that were filtered
through a 70μm cell strainer.
2.4. TaqMan-Based Real-Time RT-PCR Assays for mRNA
Expression. Quantitative real-time PCR for IFNα (n = 12),
IFNβ, and IFNγ was carried out with the LightCycler 480
instrument (Roche, Basel, Switzerland). Briefly, total RNA
was extracted from PBMCs and LPLs using the RNeasy Plus
Universal Tissue Mini Kit (Invitrogen, Carlsbad, CA, USA)
and reverse transcribed using the High Capacity cDNA
Reverse Transcription Kit (Applied Biosystems, USA),
according to the manufacturer’s protocol. Primers and
probes for each gene were added to the Probes Master Mix
(Roche, Basel, Switzerland) at 500 and 250 nM, respectively,
in a final volume of 20μL. The housekeeping gene β-glucu-
ronidase [11] was used as an internal control. Gene expres-
sion values were calculated by the comparative Ct method.
The primers and probe were assayed on demand and were
purchased from Integrated DNA Technologies (IDT), Iowa,
USA. The list of primers and probes is as follows: IFNα1
(Hs.PT.58.46311748.g), IFNβ (Hs. PT.58.39481063.g),
IFNα2 (Hs.PT.58.24294810.g), IFNα4 (Reference number:
68098028), IFNα5 (Hs.PT.58.39565646.g), IFNα6 (Hs.PT.
58.40193986.g), IFNα7 (Hs.PT.58.25568785.g), IFNα8
(Hs.PT.58.40433689.g), IFNα10 (Hs.PT.58.24640720.g),
IFNα14 (Reference number: 68098032), IFNα16 (Hs.PT.
58.1479042.g), IFNα17 (Reference number: 68098036),
IFNα21 (Hs.PT.58.45746476.g), and IFNγ (Hs.PT.58.3781960.g).
2.5. Statistical Analysis. Data are expressed as median/range.
Differences in the levels of type I and II IFN genes between
GALT and PBMC were evaluated using the Wilcoxon test.
The same test was used to evaluate changes in all type I and
II IFN genes before and after six months of probiotic supple-
mentation. Differences were considered statistically signifi-
cant when p < 0 05. All analyses were performed with the
SPSS v.17.0 for Windows.
3. Results
Transcript levels of several IFNα subtypes (n = 12), IFNβ,
and IFNγboth inPBMCandGALTweremeasured in10ART-
treated HIV-1-infected patients (gender: 100% males, age
(median/range): 42/22–53 years, CD4+ T cell count (median/
range): 674/564–824 cells/mm3, HIV-1 RNA: <37copies/mL,
duration of antiretroviral therapy (median/range): 6/1.75–
16.25 years).
Levels of all IFNα subtypes and IFNβ were higher in
GALT than in PBMC (p < 0 05 for all genes, Figures 1(a)–
1(d)). Specifically, an average of 50-fold increase of IFNα/β
subtypes in GALT compared to PBMC was recorded. The
following type I IFN exhibited the highest and lowest differ-
ences between the two anatomical sites analyzed: IFNα21
(72 times) and IFNα2 (17 times). Conversely, IFNγ gene
expression was higher (approximately 14-fold) in PBMC
compared with GALT (Figure 1(d)). Although a different
IFNα subtype expression pattern was observed in GALT
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and peripheral blood, some similarities in type I IFN signa-
ture have emerged (Figure 2). In particular, the highest and
lowest IFNα subtypes expressed were IFNα2 and IFNα6/α7,
α10, respectively.
We found that IFNα subtypes, IFNβ, and IFNγ transcript
levels as well as the IFNα subtype expression profile changed
after probiotic supplementation (Figures 1(a)–1(d)). In
particular, IFNα6, IFNα10, IFNα14, IFNα17, and IFNα21
significantly increased after probiotic treatment in both
GALT and PBMC of HIV-1-positive patients (Figures 1(b)
and 1(c)). Interestingly, by contrast to what observed for
IFNα6, IFNα10, IFNα14, IFNα17, and IFNα21 subtypes,
IFNγ levels decreased significantly in both anatomical sites
after probiotic supplementation (Figure 1(d)). For the other
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Figure 1: Expression of IFNα subtypes (n = 12), IFNβ, and IFNγ in gut-associated lymphoid tissue (GALT) and peripheral blood
mononuclear cells (PBMCs) from treated HIV-1-positive patients before (T0, white colour) and after 6 months (T6, grey colour) of
probiotics supplementation (n = 10). Panels (a–d) data were analyzed using the Wilcoxon test. Differences were considered statistically
significant when p < 0 05. ∗ Significant differences (p < 0 05) between GALT and peripheral blood (T0); ∗∗ significant differences (p < 0 05)
between GALT and peripheral blood (T6); ∗∗∗ significant differences (p < 0 05) between T0 and T6.
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type I IFN genes analyzed, we observed a reduction or an
increment depending on the specific type I IFN considered,
but the differences did not reach statistical significance.
4. Discussion
Four major points emerged from our current analysis of type
I/II IFN response in GALT and PBMC of HIV-1-infected
patients before and after probiotic treatment: (1) all IFNα
subtypes and IFNβ are more strongly expressed in GALT
than in PBMC whereas IFNγ exhibits an opposite trend; (2)
IFNα subtype expression signature in GALT is different from
the signature in PBMC; (3) levels of the IFNα subtypes and
their signature significantly change after probiotic supple-
mentation; and (4) probiotic supplementation is associated
with a decrease of the IFNγ levels. Overall, the results are very
clear; their interpretation however requires much attention
and caution.
The very high endogenous expression of all IFNα/β
subtypes in GALT could be sustained by the chronic stimula-
tion of pattern recognition receptors by intestinal bacteria
ligands which subsequently drive the production of type I
IFN [6]. The levels of IFNα subtypes and IFNβ could also
be enhanced in a situation of gut microbiota dysbiosis in
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Figure 2: IFNα subtype signature in gut-associated lymphoid tissue (GALT) and peripheral blood mononuclear cells (PBMCs) from treated
HIV-1-positive patients before (T0) and after 6 months (T6) of probiotic supplementation. Pie chart represents the expression of each IFNα
subtype. Data are expressed as percentage.
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HIV-1-positive patients, where there is an expansion of the
species belonging to the Proteobacteria phylum [12–14].
Even specific, and/or previously undescribed viruses, within
the gut virome, might contribute to the production of type
I IFN [15].
Regardless of the differences in the relative abundance of
each IFNα subtype between the two anatomical sites, it is also
important to emphasize that the profile of IFNα subtype
expression differs in GALT and PBMC during HIV-1 infec-
tion. A distinct profile of IFNα subtype expression could
suggest that not all subtypes play a negative role in chronic
HIV-1 infection. Directly related to the latter, we found that
probiotic supplementation can modulate type I IFN subtype
expression differentially, causing a significant induction of
IFNα6, IFNα10, IFNα14, IFNα17, and IFNα21 in both the
GALT and PBMC of HIV-1-infected patients. Interestingly,
four of these IFNα subtypes, IFNα6, IFNα14, IFNα17, and
IFNα21, exhibited a more potent antiviral activity against
HIV-1 compared to other subtypes [8]. In particular, IFNα14
had the ability to reduce both viremia and proviral loads
in vivo [8, 16], while another study on mice has shown the
potency of IFNα8, IFNα14, and IFNα6 in inhibiting produc-
tive HIV-1 infection [17].
It is also noteworthy that a preferential upregulation of
IFNα2 was recorded in both anatomical sites. In agreement,
the IFNα2 subtype was the most strongly expressed in the
PBMC and plasmacytoid dendritic cells of HIV-1 patients
[18], although this subtype exhibited relatively weak anti-
HIV-1 activity [8].
Conversely, a reduction of IFNγ, which has an opposite
trend of expression to IFNα/β subtypes in GALT and PBMC,
was observed after probiotic treatment in both the ana-
tomical sites analyzed. A significant steadily increasing trend
in IFNγ levels in chronic progressive HIV-1 disease has been
demonstrated [19], suggesting that probiotics can also
improve this immunologic response in HIV-1-infected
patients. The lack of a comparison of the IFN levels between
HIV-1-infected patients and a healthy control represents a
limitation of this pilot study. This analysis is needed to ascer-
tain whether changes in IFN expression might be beneficial
or detrimental to HIV-1-positive patients. However, the
reduction of IFNγ levels in both PBMC and GALT after
supplementation could serve as a suggestive control indi-
cator that the probiotic is behaving beneficially for HIV-
1-infected patients. Indeed, an excess of mucosal mRNA
expression of IFNγ has been reported to be associated with
high levels of HIV-1 replication and profound CD4+ T-cell
depletion [20].
This finding was also strongly supported by our previ-
ous studies on the same probiotic formulation, in which its
ability to reduce several biomarkers of inflammation was
showed. In particular, the probiotic product employed in
our study, when supplemented for 6 months in HIV-1-
positive patients, was associated with a significant reduction
of GALT-associated indoleamine 2,3-dioxygenase (IDO)
mRNA levels. This enzyme plays a key role in the tryptophan
metabolism and is involved in the chronic immune activation
status of patients with HIV-1 infection [9, 21]. Moreover, a
reduction in the frequencies of CD4+ and CD8+ T-cell
subsets, expressing CD38+, HLA-DR+, or both, and an
increase in the percentage of Th17 cell subsets, especially
those with central or effector memory phenotype, were
recorded in the peripheral blood and in GALT after the same
probiotic intervention [10]. Probiotic supplementation was
also associated to a recovery of the integrity of the gut epithe-
lial barrier, a reduction of both intraepithelial lymphocytes
density and enterocyte apoptosis and an improvement of
mitochondrial morphology sustained in part by a modula-
tion of heat shock protein 60 [10].
Altogether, the results of this study should be taken with
caution since it is a pilot, nonrandomized single arm, clinical
study on the effects of this specific probiotic on type I and II
IFN response in HIV-1-infected patients. Nevertheless, it
provides the first evidence that all IFNα subtypes, IFNβ,
and IFNγ are differentially expressed in the GALT and
PBMC of ART-treated HIV-1-infected patients, and this
multistrain probiotic supplementation can change the
expression of some IFNα subtypes and IFNγ, highlighting
the important role of gut microbiome composition in reg-
ulating the type I and II IFN response and providing the basis
for a well-executed large clinical trial, including healthy con-
trols. Moreover, since HIV-1 infection is characterized by a
persistent immune activation [22], the analysis of IFN
response concomitant with measures of well-established
immunological markers (e.g., interleukin-6 (IL-6), lipopoly-
saccharide binding protein (LBP), and CD4 counts) should
be performed in HIV-1-infected patients to ascertain the
potential benefit of this probiotic supplementation.
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